NSAID–antihypertensive combinations may risk kidney damage

Physicians should be aware that treating patients with a combination of antihypertensives along with nonsteroidal anti-inflammatory drugs (NSAIDs) may cause kidney damage, say researchers.

"In particular, major attention should be paid early in the course of treatment, and a more appropriate use and choice among the available anti-inflammatory or analgesic drugs could therefore be applied in clinical practice," suggest Samy Suissa (McGill University, Montreal, Quebec, Canada) and colleagues.

The team's analysis showed that a triple therapy combination consisting of a diuretic, an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), and an NSAID was associated with a substantially increased risk for acute kidney injury.

Using information from the UK Clinical Practice Research Datalink and the Hospital Episodes Statistics Database, the team found that of 487,372 individuals prescribed antihypertensives between 1997 and 2008, 2215 developed acute kidney injury over a mean follow-up period of 5.9 years.

Analysis showed no increased risk among patients taking NSAIDs at the same time as receiving antihypertensive monotherapy with a diuretic, ACE inhibitor, or ARB.

However, patients who took NSAIDs concurrently with the combination of a diuretic and ACE inhibitor or ARB had a 31% increased risk for acute kidney injury, driven primarily by a nearly twofold increased risk in the first 30 days of treatment.

"Although the basis of this is still unclear, it might be explained by an early and severe deteriorating effect of NSAIDs in susceptible patients, who are heavily dependent on prostacyclins to maintain renal function," say Suissa and team. "Furthermore, patients may initially use a greater number of NSAID pills early on than later, as some causes of pain may abate over time."

Given the wide use of NSAIDs, increased vigilance may be warranted when such a triple combination is used, says the team.

Licensed from medwireNews with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.

Sally Robertson

Written by

Sally Robertson

Sally first developed an interest in medical communications when she took on the role of Journal Development Editor for BioMed Central (BMC), after having graduated with a degree in biomedical science from Greenwich University.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Robertson, Sally. (2020, April 02). NSAID–antihypertensive combinations may risk kidney damage. News-Medical. Retrieved on November 06, 2024 from https://www.news-medical.net/news/20130114/NSAIDantihypertensive-combinations-may-risk-kidney-damage.aspx.

  • MLA

    Robertson, Sally. "NSAID–antihypertensive combinations may risk kidney damage". News-Medical. 06 November 2024. <https://www.news-medical.net/news/20130114/NSAIDantihypertensive-combinations-may-risk-kidney-damage.aspx>.

  • Chicago

    Robertson, Sally. "NSAID–antihypertensive combinations may risk kidney damage". News-Medical. https://www.news-medical.net/news/20130114/NSAIDantihypertensive-combinations-may-risk-kidney-damage.aspx. (accessed November 06, 2024).

  • Harvard

    Robertson, Sally. 2020. NSAID–antihypertensive combinations may risk kidney damage. News-Medical, viewed 06 November 2024, https://www.news-medical.net/news/20130114/NSAIDantihypertensive-combinations-may-risk-kidney-damage.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New analysis confirms canagliflozin's cardiovascular and kidney benefits in older adults